利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.07 秒)

    Recombinant protein production with reduced expression of selectable markers
    5.
    发明授权
    Recombinant protein production with reduced expression of selectable markers 失效
    重组蛋白生产与选择性标记的表达降低

    公开(公告)号：US5716803A

    公开(公告)日：1998-02-10

    申请号：US6863

    申请日：1993-01-21

    申请人： Nikos Panayotatos

    发明人： Nikos Panayotatos

    IPC分类号： C07K14/525 ,  C12N1/21 ,  C12N15/67 ,  C12N15/70 ,  C12P21/00 ,  C07H21/04 ,  C12N15/63 ,  C12N15/65

    CPC分类号： C07K14/525 ,  C12N15/67 ,  C12N15/70

    摘要： The present invention relates to expression of recombinant proteins by use of a bacterial host expression vector which expresses a recombinant protein under the control of a first regulatory expression element, and expresses a selectable marker under the control of a second regulatory expression element, which second element is mutated such that expression of the selectable marker is at reduced levels relative to that directed by such an unmutated expression element. Such an expression vector in a suitable bacterial host (a) allows ease of purification of the recombinant protein of interest ("the recombinant protein") since less selectable marker is present to interfere with the purification of the recombinant protein, and (b) increases the amount of recombinant protein that is produced by the bacterial host cell. Furthermore, in an embodiment in which the selectable marker is an antibiotic resistance gene, expression according to the present invention ensures that only the minimal necessary levels of antibiotic will be used for selection during fermentation. The invention provides expression vectors, host-vector expression systems (comprising the expression vector in a bacterial host in which it can be expressed), and methods relating thereto.

    摘要翻译： 本发明涉及通过使用表达在第一调节表达元件控制下的重组蛋白的细菌宿主表达载体表达重组蛋白，并在第二调控表达元件的控制下表达选择性标记，该第二元件 被突变，使得可选择标记的表达相对于由这种未突变的表达元件引导的表达降低。 由于存在较少的选择性标记以干扰重组蛋白的纯化，所以在合适的细菌宿主（a）中的这种表达载体允许容易地纯化目标重组蛋白（“重组蛋白”），和（b）增加 由细菌宿主细胞产生的重组蛋白的量。 此外，在选择性标记是抗生素抗性基因的实施方案中，根据本发明的表达确保了在发酵期间仅将最低限度的必需水平的抗生素用于选择。 本发明提供表达载体，宿主 - 载体表达系统（包括在其中可以表达的细菌宿主中的表达载体）以及与其相关的方法。

    Use of protein occlusion for the selective delivery of small molecules to targets
    6.
    发明申请
    Use of protein occlusion for the selective delivery of small molecules to targets 审中-公开

    公开(公告)号：US20060269478A1

    公开(公告)日：2006-11-30

    申请号：US11497684

    申请日：2006-08-01

    申请人： Nikos Panayotatos

    发明人： Nikos Panayotatos

    IPC分类号： A61K51/00 ,  A61K38/20 ,  A61K38/19

    CPC分类号： A61K47/62

    摘要： The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of this invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.

    Protein occlusion for delivery of small molecules
    9.
    发明授权
    Protein occlusion for delivery of small molecules 失效
    用于递送小分子的蛋白质闭塞

    公开(公告)号：US06406710B1

    公开(公告)日：2002-06-18

    申请号：US09101860

    申请日：1998-07-16

    申请人： Nikos Panayotatos

    发明人： Nikos Panayotatos

    IPC分类号： A61F202

    CPC分类号： A61K47/62

    摘要： The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of thus invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.

    摘要翻译： 本发明涉及（1）靶结合部分之间的复合物; （2）空腔形成部分; 和（3）待递送至靶的药物化合物，其中所述药理学化合物被掩埋在所述空腔形成部分的内部，但不共价结合于靶结合部分或空腔形成部分。 本发明的复合物可以用于将药物化合物递送到细胞，组织，器官，病毒，微生物或其它表面，其特征在于结合复合物的靶结合部分部分的实体。 本发明还涉及包含本发明的非共价复合物的药物组合物。 本发明还涉及将药物化合物递送至患者中的靶标的方法。 本发明还涉及本发明的复合物用于将化学实体与其手性形式或污染物分离的用途。

    ERK3 MAP2 protein kinase
    10.
    发明授权
    ERK3 MAP2 protein kinase 失效
    ERK3 MAP2蛋白激酶

    公开(公告)号：US06303358B1

    公开(公告)日：2001-10-16

    申请号：US08888818

    申请日：1997-07-07

    申请人： Teri G. Boulton ,  Melanie H. Cobb ,  George D. Yancopoulos ,  Steven Nye ,  Nikos Panayotatos

    发明人： Teri G. Boulton ,  Melanie H. Cobb ,  George D. Yancopoulos ,  Steven Nye ,  Nikos Panayotatos

    IPC分类号： C12N912

    CPC分类号： G01N33/5041 ,  C12N9/12 ,  C12Q1/485 ,  G01N33/5008 ,  G01N33/573 ,  G01N2333/9121 ,  G01N2500/00

    摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease, peripheral neuropathies, and diabetes may be identified using the methods of the invention.

    摘要翻译： 本发明涉及磷酸化微管相关蛋白2（MAP2）的新鉴定的蛋白丝氨酸/苏氨酸激酶家族。 它部分地基于在中枢神经系统中表达的称为细胞外信号调节激酶1,2和3（ERK1，ERK2，ERK3）的新型MAP2激酶的克隆和表征，以及鉴定另一种 ERK家族成员，ERK4，具有抗血清。 本发明提供了代表MAP2激酶家族成员的重组核酸分子和蛋白质，还提供了包含重组MAP2激酶分子的微生物，转基因动物和细胞系。 在本发明的另外的实施方案中，本发明提供了测定细胞因子活性的方法，包括但不限于神经生长因子活性，其中MAP2激酶的活化用作细胞因子活性的指标。 这些方法在筛选化合物中以期存在所需的细胞因子活性可能是非常有用的。 在具体实施方案中，可以使用本发明的方法鉴定可用于治疗阿尔茨海默氏病，周围神经病和糖尿病的化合物。